Universal CAR T-Cells tested as potential reset for stubborn autoimmune diseases

NCT ID NCT07410377

Summary

This early-phase study is testing a new type of 'off-the-shelf' CAR T-cell therapy for people with severe, hard-to-treat autoimmune diseases like lupus and inflammatory myopathy. The therapy uses immune cells from a healthy donor, modified to target and remove certain harmful B cells, and is given as a single infusion. Researchers will primarily check if the treatment is safe and tolerable, and also look for signs that it can reduce disease activity.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • The Affiliated Hospital of Xuzhou Medical University

    Xuzhou, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.